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ABSTRACT 
Co-delivery systems have been proved to be of much benefit to the anti-cancer drug field. In order to make these drugs successful, 
nano-particles usage has been promoted. The mini-review has brought forward some of the most prominent co-delivery 
developments in the field, especially with paclitaxel. The discussion here is never meant to be comprehensive, but to give some new 
trends and highlights within this area. 




Throughout the recent decades, there has occurred an 
enormous rise in the polymer micelles potential usage as 
anti-cancer drugs delivery vehicles.
1-5
 These vehicles 
have definitely offered some significant insight to the 
way in which treatment can be enforced effectively.
6-10
 
This paper has selected various journal articles showing 
the same and proving to be essential in the field. 
Co-delivering paclitaxel and Herceptin  
The article by Lee reports the use of a copolymer which 
is biodegradable as well as amphiphilic in nature.
11
 The 
copolymer is used to obtain self-assembled micellar 
nanoparticles.
6,12
 The copolymer is termed as poly co 
ammonium bromide sebacate, P (MDS-co-CES). These 
had the ability to deliver the drugs as well as bio-macro 
molecules.
13
 These included genes as well as proteins of 
functional nature either in a simultaneous manner or 
individual manner within several cell types.
14,15
 Within 
this article, such nanoparticles were taken into 
consideration which had cationic micellar nature. These 
were used as a medium to carry for co-delivering 
paclitaxel as well as Herceptin. This was done to 
achieve paclitaxel targeted delivery for receptor 2 
growth factor in the epidermis of humans. This was 
done to suppress toxicity of the cells by activities of 
synergistic nature. Nanoparticles loaded with Paclitaxel 
have a size of average nature lesser than 120 nm and 
there is a potential of zeta potential for about 60 mV. 
The complexion of Herceptin was done on the 
nanoparticles surface.
16
 The nano-particle drug loading 
complication continued to have stability under 
conditions of physiological simulation with 200 nm 
sizes. Herceptin was delivered by nanoparticles in an 
efficient manner than the bioPorter. This is a protein 
carrier with lipid base available commercially. The 
nano-particles with Herceptin depicted an effectiveness 
of anti-cancer highly. Daily treatment was repeated 
twice with the element of Herceptin depicting high cell 
toxicity significantly and particularly within 
overexpressed cancer cells in the breast in comparison to 
any individual treatment. Effects of anti-cancer coming 
from such a co-delivery system were thoroughly 
investigated within the cancer cells of the human breast. 
This was completed in alignment with several ranges of 
the expression level of Her2. These were inclusive of 
BT474, T47D, and MCF7. The Herceptin co-delivery 
enhanced the paclitaxel cytotoxicity and such 
enhancement depicted to be dependent on the expression 
levels of HER2. This co-delivery system targeted 
ability, within the article, was shown by images of 
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confocal nature. This depicted a higher uptake of 
cellular nature significantly. This was taken up by the 
BT474 overexpressed cells of HER2 in comparison to 
the negative HER3 negative cells of HEK293. This 
system of co-delivery might have essential implications 
clinically against the overexpressed cancer cells in the 
breast.  
Co-delivering siRNA and paclitaxel  
Preparation of biodegradable cation micelles was done 
from the triblock copolymer of PDMAEMA-PCL-
PDMAEMA and applicable for the siRNA delivery as 
well as paclitaxel over the cells of cancer.
17
 The 
copolymers of PDMaEMA-PCL-PDMAEMA were 
gained readily through the reversed chain transfer of 
additional fragmentation (also known as RAFT) with 
dimethylamino ethyl methacrylate polymerization. This 
was done through the use of CPAD-PCL-CPADN (4-
cyanopentanoic acid dithionaphthalenoate) as an agent 
of micro-RAFT.
18
 The PDMAEMA blocks molecular 
weights under the control of monomer ranged from 
2700 to 9100. Such copolymers with triblocking 
resulted in the formation of water-based nano-sized 
micelles with positive charges over the surface. These 
ranged from 29.5 and 35.5 mV. A low cytotoxicity was 
revealed by micelles 1 and 2. The assay test of gel 
retardation depicted that first and second micelles could 
complicate effectively with the use of siRNA as well as 
over the ratios of N/P for 4/2 and 2/1. The GFP siRNA 
notably having complexed with the 1st micelle depicted 
enhanced significance for gene silencing.
19-21
 It depicted 
more efficiency in comparison to the 20 kDa 
PDMAEMA formulation. 1st micelle, moreover, loaded 
with the enzyme of paclitaxel depicted higher efficacy 
for drug compared with PC2 cells with free paclitaxel. 
This is because of most likeliness for cellular uptake 
improvement. The VEGF siRNA combined delivery, as 
well as paclitaxel, depicted a VEGF expression efficient 
knockdown. Studies using confocal laser scanning 
microscope over GFP siRNA complexed with micelle 
having nile red loading depicted that nile red could be 
delivered within the MDA-MB-435-GFP. This was 
expressed by GFP cells. Such expression of GFP was 
inhibited significantly. Such results showed that 
biodegraded micelles with cations have more promise 
for the siRNA and lipophile combined delivery for anti-
cancer drugs.  
Co-delivering doxorubicin and paclitaxel  
The research by Wang et al. stated that using the single 
drug for chemotherapy has shown certain anti-tumor 
treatment limitations.
22
 When combining the drugs, it 
results in better performance. In this article, the authors 
proposed minimizing each drug’s amount. This was 
done to gain the effect of synergistic nature for therapies 
of cancer. Various researchers have attempted to deliver 
drugs with chemotherapeutics in a simultaneous manner 
through the use of carriers of drugs such as liposomes, 
micelles, and nanoparticles of inorganic nature. The 
article reported nanoparticles with core shells to be 
emulsified in a double manner from copolymers having 
amphiphilic nature. The copolymer used by them was 
methoxy poly (ethylene glycol)-poly (lactide-co-
glycolide). Such nanoparticles resulted in offering 
benefits over related nano-carriers because they had the 
ability of easy fabrication. This was done through an 
improvised method for double emulsion known as 
biocompatibility. It showed higher efficacy for loading. 
More significantly, these nanoparticles had the ability of 
co-delivering doxorubicin of hydrophilic nature as well 
as paclitaxel of hydrophobic nature. 
23,24
The 
nanoparticles loaded with the drug, had a good ability to 
polydisperse. This depicted that they were subjected 
more readily to controlled distribution of size. Drug 
release studies, as well as co-delivery systems cellular 
uptake, depicted that the drugs were taken up effectively 
through cells and simultaneously released.  
Co-delivering tariquidar and paclitaxel  
The study by Patel et al. proposed that p-gp inhibitors 
with higher efficacious ability are to be used to show 
success to overcome MDR.
25
 Such inhibitor is taken in 
the article as tariquidar.
26
 P-gp, however, can further be 
expressed within general tissues such as the barriers in 
the blood brain, track of gastrointestinal nature, spleen 
as well as kidney. For maximizing the P-gp inhibitor 
efficacy as well as reducing the toxicity systemically, it 
becomes essential to consider limiting the P-gp 
inhibitors exposure as well as the drugs of anti-cancer 
for normal tissues. This further results in increasing the 
tumor cells co-localization. Within the article, the 
authors indulged in investigating the P-gp inhibitor co-
delivery and drug of cytotoxic nature, namely paclitaxel 
within the cells of the tumor for reversing the MDR 
(multi-drug resistance) through the use of liposomes 
with long circulation. These liposomes along with 
tariquidar depicted essential resistant variant re-
sensitization for the paclitaxel-resistant variance. This 
could have a correlation with enhanced paclitaxel 
accumulation within the cells of the tumor.   
Co-delivering paclitaxel and siRNA with 
lipid nanoparticle 
According to the discovery by Yu et al., nano-particles 
with cationic solids of lipids were formulated for 
paclitaxel co-delivery with siRNA.
27
 Methods of 
emulsification solidification were used for preparing 
cslN based on 1.2-Dioleoyl-sn-glycero-
3ethylphosphochonline. 
28-30
 Zeta potential was used for 
characterizing the cSLN loaded with PTX as well as 
retardation of gels with small interfering RNA 
complexes. The PcSLN sizes were not essentially 
different from the empty cSLN. The cSLN utilization 
enhanced the uptake at the cellular level of dsRNA 
fluorescence within the carcinoma KB cells. These cells 
are present in the epithelium of humans. This is further 
combined with PcSLN complexing it to dsRNA labeled 
through fluorescence. This results in promotion of 
maximum uptake. For therapeutic siRNA co-delivery, 
siRNA specific MCL1 for humans was complexed 
around PcSLN. The control in this situation was the 
complexion of siRNA specific to luciferase over 
PcSLN. The levels of MC1 mRNA were reduced in an 
essential manner within the cells of KB undergoing 
treatment with the complexion of siMCL over PcSLN. 
Collectively, the article demonstrated the cSLN 
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potential for developing various lipophile based drugs 
for anti-cancer co-delivery systems as well as siRNAs 
therapeutically.  
CONCLUSION  
This is to conclude that there have been several 
developments in the cancer treatment field. However, 
multi-drug resistant has remained a concurring 
problem.
31-34
 All the articles being discussed in this 
paper comprise of solutions for co-delivering drugs to 
help in efficiency of anti-cancer drugs.
35-37
 It can be 
concluded that synergistically combining 2 or more than 
2 drugs is a strategy of promising nature.  
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